BACKGROUND: HIV-1 mother-to-child transmission (MTCT) remains an important route of infection in sub-Saharan Africa. METHODS: Genetic variants in CCR5 promoter, CCR2, CX3CR1, and Stromal cell-derived factor-1 (SDF-1) genes were determined in 980 infants from sub-Saharan Africa using real-time polymerase chain reaction to determine association with MTCT. RESULTS: In antiretroviral-naive mother-infant pairs (n = 637), CCR5 promoter polymorphisms at positions 59029: A allele vs. G/G [odds ratio (OR): 1.61, 95% confidence interval (CI): 1.04 to 2.48; P = 0.032] and 59356: T allele vs. C/C (OR: 0.63, 95% CI: 0.41 to 0.96; P = 0.033) and CCR2-180: G allele vs. A/A (OR: 3.32, 95% CI: 1.13 to 9.73; P = 0.029) were associated with risk of MTCT. Treatment of HIV-1-infected mothers and infants with single-dose nevirapine or perinatal zidovudine altered but did not eliminate the association of genetic variants with MTCT. CONCLUSIONS: CCR5 promoter, CCR2, and CX3CR1 polymorphisms were associated with risk of MTCT likely through their role as an HIV-1 coreceptor or by modulating the early immune response. Host genetics may continue to alter MTCT when short-course interventions that only partially suppress virus are used. These findings will need to be confirmed in validation cohorts with a large number of infected infants.
BACKGROUND:HIV-1 mother-to-child transmission (MTCT) remains an important route of infection in sub-Saharan Africa. METHODS: Genetic variants in CCR5 promoter, CCR2, CX3CR1, and Stromal cell-derived factor-1 (SDF-1) genes were determined in 980 infants from sub-Saharan Africa using real-time polymerase chain reaction to determine association with MTCT. RESULTS: In antiretroviral-naive mother-infant pairs (n = 637), CCR5 promoter polymorphisms at positions 59029: A allele vs. G/G [odds ratio (OR): 1.61, 95% confidence interval (CI): 1.04 to 2.48; P = 0.032] and 59356: T allele vs. C/C (OR: 0.63, 95% CI: 0.41 to 0.96; P = 0.033) and CCR2-180: G allele vs. A/A (OR: 3.32, 95% CI: 1.13 to 9.73; P = 0.029) were associated with risk of MTCT. Treatment of HIV-1-infected mothers and infants with single-dose nevirapine or perinatal zidovudine altered but did not eliminate the association of genetic variants with MTCT. CONCLUSIONS:CCR5 promoter, CCR2, and CX3CR1 polymorphisms were associated with risk of MTCT likely through their role as an HIV-1 coreceptor or by modulating the early immune response. Host genetics may continue to alter MTCT when short-course interventions that only partially suppress virus are used. These findings will need to be confirmed in validation cohorts with a large number of infected infants.
Authors: G C John; C Rousseau; T Dong; S Rowland-Jones; R Nduati; D Mbori-Ngacha; T Rostron; J K Kreiss; B A Richardson; J Overbaugh Journal: J Virol Date: 2000-06 Impact factor: 5.103
Authors: J P Teglas; N N'Go; M Burgard; M J Mayaux; C Rouzioux; S Blanche; J F Delfraissy; M Misrahi Journal: J Acquir Immune Defic Syndr Date: 1999-11-01 Impact factor: 3.731
Authors: H Behbahani; E Popek; P Garcia; J Andersson; A L Spetz; A Landay; Z Flener; B K Patterson Journal: Am J Pathol Date: 2000-12 Impact factor: 4.307
Authors: S Faure; L Meyer; D Costagliola; C Vaneensberghe; E Genin; B Autran; J F Delfraissy; D H McDermott; P M Murphy; P Debré; I Théodorou; C Combadière Journal: Science Date: 2000-03-24 Impact factor: 47.728
Authors: G C John; T Bird; J Overbaugh; R Nduati; D Mbori-Ngacha; T Rostron; T Dong; L Kostrikis; B Richardson; S L Rowland-Jones Journal: J Infect Dis Date: 2001-05-31 Impact factor: 5.226
Authors: L G Kostrikis; A U Neumann; B Thomson; B T Korber; P McHardy; R Karanicolas; L Deutsch; Y Huang; J F Lew; K McIntosh; H Pollack; W Borkowsky; H M Spiegel; P Palumbo; J Oleske; A Bardeguez; K Luzuriaga; J Sullivan; S M Wolinsky; R A Koup; D D Ho; J P Moore Journal: J Virol Date: 1999-12 Impact factor: 5.103
Authors: L Ometto; M Zanchetta; M Mainardi; G L De Salvo; M C Garcia-Rodriguez; L Gray; M L Newell; L Chieco-Bianchi; A De Rossi Journal: AIDS Date: 2000-08-18 Impact factor: 4.177
Authors: Despina G Contopoulos-Ioannidis; Thomas R O'Brien; James J Goedert; Phillip S Rosenberg; John P A Ioannidis Journal: J Acquir Immune Defic Syndr Date: 2003-01-01 Impact factor: 3.731
Authors: Stephen A Spector; Kumud K Singh; Saurabh Gupta; Lucette A Cystique; Hua Jin; Scott Letendre; Rachel Schrier; Zunyou Wu; Kun X Hong; Xin Yu; Chuan Shi; Robert K Heaton Journal: AIDS Date: 2010-06-19 Impact factor: 4.177
Authors: Sharon Shalekoff; Stephen Meddows-Taylor; Diana B Schramm; Glenda Gray; Gayle Sherman; Ashraf Coovadia; Louise Kuhn; Caroline T Tiemessen Journal: AIDS Res Hum Retroviruses Date: 2009-10 Impact factor: 2.205
Authors: Marie Nicole Ngoufack; Céline N Nkenfou; Barbara A Tiedeu; Georges Nguefack-Tsague; Linda C Mekue Mouafo; Beatrice Dambaya; Carine N Nguefeu; Elvis N Ndzi; Serge C Billong; Wilfred F Mbacham; Alexis Ndjolo Journal: Int J Biochem Mol Biol Date: 2019-10-15
Authors: D A Katz; G C John-Stewart; B A Richardson; M Majiwa; J M Mabuka; B Lohman-Payne; C Farquhar Journal: Int J Immunogenet Date: 2010-05-27 Impact factor: 1.466
Authors: Geneviève Boily-Larouche; Anne-Laure Iscache; Lynn S Zijenah; Jean H Humphrey; Andrew J Mouland; Brian J Ward; Michel Roger Journal: PLoS One Date: 2009-10-07 Impact factor: 3.240